Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan

References

• Goto H, Nakatani E, Yagi H, et al. Late-onset development of psoriasis in Japan: a population-based cohort study. JAAD Int. 2021;2:1–10. doi: 10.1016/j.jdin.2020.10.011.
   PubMedGoogle Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84–91. doi: 10.1001/2013.jamadermatol.406.
   PubMed Web of Science ®Google Scholar
• Gui XY, Jin HZ, Wang ZJ, et al. Serum uric acid levels and hyperuricemia in patients with psoriasis: a hospital-based cross-sectional study. An Bras Dermatol. 2018;93(5):761–763. doi: 10.1590/abd1806-4841.20187547.
   PubMed Web of Science ®Google Scholar
• Kamiya K, Kishimoto M, Sugai J, et al. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347. doi: 10.3390/ijms20184347.
   PubMed Web of Science ®Google Scholar
• Dhana A, Yen H, Yen H, et al. All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(5):1332–1343. doi: 10.1016/j.jaad.2018.12.037.
   PubMed Web of Science ®Google Scholar
• Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med (Lausanne). 2021;8:743180. doi: 10.3389/fmed.2021.743180.
   PubMed Web of Science ®Google Scholar
• Saeki H, Mabuchi T, Asahina A, et al. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). J Dermatol. 2022;50(5):e138–e150. doi: 10.1111/1346-8138.16691.
   Web of Science ®Google Scholar
• Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47(3):201–222. doi: 10.1111/1346-8138.15196.
   PubMed Web of Science ®Google Scholar
• Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297. doi: 10.3390/ijms18112297.
   PubMed Web of Science ®Google Scholar
• Tada Y, Ishii K, Kimura J, et al. Patient preference for biologic treatments of psoriasis in Japan. J Dermatol. 2019;46(6):466–477. doi: 10.1111/1346-8138.14870.
   PubMed Web of Science ®Google Scholar
• Sruamsiri R, Iwasaki K, Tang W, et al. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database. BMC Dermatol. 2018;18(1):5. doi: 10.1186/s12895-018-0074-0.
   PubMedGoogle Scholar
• Chastek B, White J, Van Voorhis D, et al. A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in adult US managed care patients. Adv Ther. 2016;33(4):626–642. doi: 10.1007/s12325-016-0312-y.
   PubMed Web of Science ®Google Scholar
• Gu T, Shah N, Deshpande G, et al. Comparing biologic cost per treated patient across indications among adult US managed care patients: a retrospective cohort study. Drugs Real World Outcomes. 2016;3(4):369–381. doi: 10.1007/s40801-016-0093-2.
   PubMedGoogle Scholar
• Doshi JA, Takeshita J, Pinto L, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US medicare population. J Am Acad Dermatol. 2016;74(6):1057–1065.e4. doi: 10.1016/j.jaad.2016.01.048.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–1158. doi: 10.1111/jdv.13611.
   PubMed Web of Science ®Google Scholar
• Zweegers J, van den Reek JM, van de Kerkhof PC, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016;175(2):340–347. doi: 10.1111/bjd.14552.
   PubMed Web of Science ®Google Scholar
• Dávila-Seijo P, Dauden E, Carretero G, et al. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol. 2016;30(11):1942–1950. doi: 10.1111/jdv.13682.
   PubMed Web of Science ®Google Scholar
• Pogácsás L, Borsi A, Takács P, et al. Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary. J Dermatolog Treat. 2017;28(7):635–641. doi: 10.1080/09546634.2017.1329504.
   PubMed Web of Science ®Google Scholar
• Iskandar IYK, Ashcroft DM, Warren RB, et al. Patterns of biologic therapy use in the management of psoriasis: cohort study from the british association of dermatologists biologic interventions register (BADBIR). Br J Dermatol. 2017;176(5):1297–1307. doi: 10.1111/bjd.15027.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519. doi: 10.1111/bjd.16102.
   PubMed Web of Science ®Google Scholar
• Masui S, Yonezawa A, Momo K, et al. Infliximab treatment persistence among Japanese patients with chronic inflammatory diseases: a retrospective Japanese claims data study. Biol Pharm Bull. 2022;45(3):323–332. doi: 10.1248/bpb.b21-00906.
   PubMed Web of Science ®Google Scholar
• Inui K, Sato M, Esterberg E, et al. Treatment practices and costs among patients with psoriatic arthritis: a Japanese hospital claims database analysis. Mod Rheumatol. 2021;31(6):1179–1191. doi: 10.1080/14397595.2021.1886629.
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Nobeyama Y, Hayashi M, et al. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 2013;40(12):1008–1013. doi: 10.1111/1346-8138.12353.
   PubMed Web of Science ®Google Scholar
• Tada Y, Kim H, Spanopoulos D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: a retrospective claims database study. J Dermatol. 2022;49(11):1106–1117. doi: 10.1111/1346-8138.16543.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. doi: 10.1056/NEJMra050100.
   PubMed Web of Science ®Google Scholar
• Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 2014;7:35–44. doi: 10.2147/RMHP.S19801.
   PubMedGoogle Scholar
• JMDC Claims Database. Available from: https://www.jmdc.co.jp/en/jmdc-claims-database/.
   Google Scholar
• International Classification of Diseases. Tenth Revision (ICD-10): Centers for Disease Control and Prevention; [updated December 29, 2021. Available from: https://www.cdc.gov/nchs/icd/icd10.htm#:∼:text=International%20Classification%20of%20Diseases%2CTenth%20Revision%20(ICD%2D10)&text=The%20International%20Classification%20of%20Diseases,and%20presentation%20of%20mortality%20statistics.
   Google Scholar
• Ciaccio EJ. Use of artificial intelligence in scientific paper writing. Inf Med Unlocked. 2023;41:101253. doi: 10.1016/j.imu.2023.101253.
   Google Scholar
• Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303–2310. doi: 10.1185/03007990903126833.
   PubMed Web of Science ®Google Scholar
• Kamiya K, Oiso N, Kawada A, et al. Epidemiological survey of the psoriasis patients in the Japanese society for psoriasis research from 2013 to 2018. J Dermatol. 2021;48(6):864–875. doi: 10.1111/1346-8138.15803.
   PubMed Web of Science ®Google Scholar
• Kishimoto M, Komine M, Kamiya K, et al. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47(1):33–40. doi: 10.1111/1346-8138.15146.
   PubMed Web of Science ®Google Scholar
• Ballegaard C, Højgaard P, Dreyer L, et al. Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken). 2018;70(4):592–599. doi: 10.1002/acr.23333.
   PubMed Web of Science ®Google Scholar
• Morita A, Kotowsky N, Gao R, et al. Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: results from the medical data vision claims database. J Dermatol. 2021;48(10):1463–1473. doi: 10.1111/1346-8138.16022.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Ohtsuki M, Sano S, et al. Switching biologics in the treatment of psoriatic arthritis in Japan. J Dermatol. 2019;46(3):e113–e4. doi: 10.1111/1346-8138.14622.
   PubMed Web of Science ®Google Scholar
• Honda H, Umezawa Y, Kikuchi S, et al. Switching of biologics in psoriasis: reasons and results. J Dermatol. 2017;44(9):1015–1019. doi: 10.1111/1346-8138.13860.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014;28(4):438–453. doi: 10.1111/jdv.12118.
   PubMed Web of Science ®Google Scholar
• Medina-Catalán D, Riera P, Pagès-Puigdemont N, et al. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. Int J Clin Pharm. 2022;44(3):725–730. doi: 10.1007/s11096-022-01400-z.
   PubMed Web of Science ®Google Scholar
• Xu C, Teeple A, Wu B, et al. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population. J Dermatolog Treat. 2022;33(4):2270–2277. doi: 10.1080/09546634.2021.1950600.
   PubMed Web of Science ®Google Scholar
• Blair HA. Risankizumab: a review in moderate to severe plaque psoriasis. Drugs. 2020;80(12):1235–1245. doi: 10.1007/s40265-020-01357-1.
   PubMed Web of Science ®Google Scholar
• Chan SA, Hussain F, Lawson LG, et al. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatolog Treat. 2013;24(1):64–69. doi: 10.3109/09546634.2011.607425.
   PubMed Web of Science ®Google Scholar
• Bolt T, Kobayashi H, Mahlich J. Patient and physician preferences for therapy characteristics for psoriasis: a discrete choice experiment in Japan. Pharmacoecon Open. 2019;3(2):255–264. doi: 10.1007/s41669-018-0104-1.
   PubMed Web of Science ®Google Scholar
• Harrold LR, Stolshek BS, Rebello S, et al. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US corrona registry. Clin Rheumatol. 2017;36(4):895–901. doi: 10.1007/s10067-017-3593-x.
   PubMed Web of Science ®Google Scholar
• Mahlich J, Sruamsiri R. Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. Patient Prefer Adherence. 2016;10:1509–1519. doi: 10.2147/PPA.S110147.
   PubMed Web of Science ®Google Scholar
• Tada Y, Jo SJ, Huang YH, et al. Uncovering the unmet needs among psoriasis patients in the Asia-Pacific region. J Dermatol. 2021;48(11):1665–1674. doi: 10.1111/1346-8138.16072.
   PubMed Web of Science ®Google Scholar
• Farahnik B, Patel V, Beroukhim K, et al. Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability. Psoriasis (Auckl). 2016;6:105–111. doi: 10.2147/PTT.S98952.
   PubMedGoogle Scholar
• Thatiparthi A, Martin A, Liu J, et al. Risk of skin cancer with phototherapy in moderate-to-severe psoriasis: an updated systematic review. J Clin Aesthet Dermatol. 2022;15(6):68–75.
   PubMedGoogle Scholar
• Schmitt-Egenolf M, Freilich J, Stelmaszuk-Zadykowicz NM, et al. Drug persistence of biologic treatments in psoriasis: a swedish national population study. Dermatol Ther (Heidelb). 2021;11(6):2107–2121. doi: 10.1007/s13555-021-00616-7.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Tian H, Wang X, et al. Health care utilization and cost associated with biologic treatment patterns among patients with moderate to severe psoriasis: analyses from a large U.S. Claims database. J Manag Care Spec Pharm. 2018;25(4):479–488. doi: 10.18553/jmcp.2018.18308.
   PubMed Web of Science ®Google Scholar
• Hur P, Kim N, Dai D, et al. Healthcare cost and utilization associated with biologic treatment patterns among patients with psoriatic arthritis: analyses from a large US claims database. Drugs Real World Outcomes. 2021;8(1):29–38. doi: 10.1007/s40801-020-00217-4.
   PubMedGoogle Scholar